Form 4: Hologic Director Stacey D. Stewart Reports Acquisition of Stock and Stock Options

Director Stacey D. Stewart reports acquisition of common stock and stock options in Hologic Inc.

Summary

• On February 26, 2025, Stacey D. Stewart, a director of Hologic Inc. (HOLX), reported the acquisition of 1,864 shares of common stock.
• Stewart also acquired 5,535 non-qualified stock options with an exercise price of $64.36, exercisable starting on the date of the 2026 Annual Meeting of Stockholders and expiring on February 26, 2035.
• Following the reported transactions, Stewart beneficially owns 5,168 shares of common stock, including 3,436 restricted stock units with deferred settlement.
• The restricted stock units vest on the date of the 2026 Annual Meeting of Stockholders and are settled in shares of common stock on a one-for-one basis.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard regulatory filing detailing stock and option acquisitions by a company director. It doesn't inherently indicate positive or negative news.

Positives

• The acquisition of stock and stock options by a director may signal confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, in their company's stock. These filings are closely watched by investors as they can provide insights into management's views on the company's prospects.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding Hologic's stock.

Next Steps

• Monitor future Form 4 filings by Stacey D. Stewart and other Hologic insiders for further insights into their investment activities.

Key Dates